CAMBRIDGE, Mass.–(BUSINESS WIRE)–Agilis Biotherapeutics, Inc. (Agilis), a biotechnology company advancing innovative DNA therapeutics for rare genetic diseases that affect the central nervous system (CNS), announced today two presentations on its gene therapy program for Angelman syndrome (AS). A poster presentation entitled, “The A-BOM: Collaborating to identify patient-centered biomarkers and outcome …
Tag Archives: Angelman syndrome
October, 2017
September, 2016
-
9 September
FDA Grants Orphan Drug Designation to Ovid’s Drug for Treatment of Angelman Syndrome
NEW YORK–(BUSINESS WIRE)– Ovid Therapeutics, a privately held biopharmaceutical company based in New York City, announced today that the U.S. Food and Drug Administration has granted orphan drug designation to OV101 for the treatment of patients with Angelman syndrome. OV101 is the first potential therapy to target the disruption of …
November, 2015
-
4 November
Agilis Biotherapeutics’ Investigational Angelman Syndrome Drug Granted Orphan Drug Status
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Agilis Biotherapeutics, LLC (Agilis), a biotechnology company advancing innovative DNA therapeutics for rare genetic diseases that affect the central nervous system (CNS), announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to AGIL-AS, the Company’s gene therapy product candidate being developed for …